Controlled and continuous release ocular drug delivery systems: Pros and cons

Current Drug Delivery

Volumn 9, Issue 4, 2012, Pages 421-430

  Abdelkader, Hamdy ^a   Alany, Raid G ^b,c  

^a Minia University   (Egypt)

^b KINGSTON UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Controlled release; Cornea; Cubosomes; Niosomes; Ocular delivery

Indexed keywords

ACETAZOLAMIDE; AMPHOTERICIN B; BETAXOLOL; CARBOMER; CELLACEFATE; CHITOSAN; CYCLOPENTOLATE; DEXAMETHASONE SODIUM PHOSPHATE; FLUCONAZOLE; GATIFLOXACIN; GELATIN; GELLAN; GENTAMICIN; LIPOSOME; METHYLPREDNISOLONE; MITOMYCIN C; MOXIFLOXACIN; NIOSOME; PILOCARPINE; POLOXAMER; POLYCARBOPHIL; POLYLACTIDE; POLYMER; POLYSACCHARIDE; SOLID LIPID NANOPARTICLE; SPARFLOXACIN; TIMOLOL; TIMOLOL MALEATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XYLOGLUCAN;

BACTERIAL INFECTION; BIOADHESIVE OPHTHALMIC DRUG INSERT; CANDIDIASIS; COLLAGEN SHIELD; CONTINUOUS RELEASE FORMULATION; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRY EYE; ENDOPHTHALMITIS; GEL; GELATION; HUMAN; HYDROCOLLOID; HYDROPHILICITY; KERATITIS; LACRIMAL DUCT; LIPOPHILICITY; MEMBRANE PERMEABILITY; MICROEMULSION; NANOPHARMACEUTICS; NANOSUSPENSION; NONHUMAN; OCULAR DRUG DELIVERY SYSTEM; OCULAR INSOLUBLE INSERT; OCULAR SOLUBLE INSERT; OINTMENT; OPHTHALMIC INSERT; PRIORITY JOURNAL; REVIEW; SUSPENSION; VESICULAR DELIVERY SYSTEM;

EID: 84863554909     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/156720112801323125     Document Type: Review

References (105)

1. Sahoo, S. K.; Dilnawaz, F.; Krishnakumar, S. Nanotechnology in ocular delivery. Drug Discov. Today, 2008, 13, 144-151.
2. Lang, J. C., Ocular drug delivery conventional ocular formulations. Adv. Drug Del. Rev., 1995, 16, 39-43.
3. Urtti, A., Ocular drug delivery. Adv. Drug Del. Rev. 2006, 58, 1129-1130.
4. Amelie, B.; Elias, F.; Jean, L. G.; Francis, P.; Patrick, C. I. J. o. P., Characterization of a new ocular delivery system based on a dispersion of liposomes in a thermosensitive gel. Int. J. Pharm., 1998, 162, 119-127.
5. Urtti, A., Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv. Drug Del. Rev., 2006, 58, 1131-1135.
6. Kaur, I. P.; Garg, A.; Aggarwal, D. Vesicular systems in ocular drug delivery: an overview. Int. J. Pharm. 2004, 269, 1-14.
7. Kaur, I. P.; Kanwar, M., Ocular preparations:the formulation approach. Drug Dev. Ind. Pharm., 2002, 28, 473-493.
8. Furrer, P.; Mayer, J. M.; Gurny, R. Ocular tolerance of preservatives and alternatives. Eur. J. Pharm. Biopharm., 2002, 53, 263-280.
9. White, C. J.; Byrne, M. E., Molecularly imprinted therapeutic contact lenses. Expert Opin. Drug Deliv., 2010, 7, 765-780.
10. du Toit, L. C.; Pillay, V.; Choonara, Y. E.; Govender, T.; Carmichael, T., Ocular drug delivery - a look towards nanobioadhesives. Expert Opin. Drug Deliv., 2011, 8, 71-94.
11. Sultana, Y.; Maurya, D. P.; Iqbal, Z.; Aqil, M., Nanotechnology in ocular delivery: current and future directions. Drugs Today, 2011, 47, 441-455.
12. Sultana, Y.; Aqil, M.; Ali, A.; Samad, A., Advances in the topical ocular drug delivery. Expert Rev. Ophthalmol., 2007, 2, 309-323.
13. Gurtler, F.; Gurny, R. Patent literature review of ophthalmic inserts Drug Dev. Ind. Pharm. 1995, 21, 1-18.
14. Rathore, K. S.; Nema, R. K., Review on ocular inserts. Int. J. Pharm. Tech. Res., 2009, 1, 164-169.
15. Baeyens, V.; Kaltsatos, V.; Boisramé, B.; Varesio, E.; Veuthey, J. L.; Fathi, M.; Balant, L. P.; Gex-Fabry, M.; Gurny, R. Optimized release of dexamethasone and gentamicin from a soluble ocular insert for the treatment of external ophthalmic infections. J. Control Rel., 1998, 52, 215-220.
16. Baeyens, V.; Felt-Baeyens, O.; Rougier, S.; Pheulpin, S.; Boisramé, B.; Gurny, R. Clinical evaluation of bioadhesive ophthalmic drug inserts (BODI®) for the treatment of external ocular infections in dogs. J. Control. Rel., 2002, 85, 163-68.
17. El Gamal, S.; Naggar, V.; Allam, A. N., Formulation and evaluation of acyclovir ophthalmic inserts. Asian J. Pharm. Sci., 2008, 3, 58-67.
18. Lee, V. H. L., Review: new directions in the optimization of ocular drug delivery. J. Ocul. Pharmacol. Ther., 1990, 6, 157-164.
19. Willoughby, C. E.; Batterbury, M.; Kaye, S. B., Collagen Corneal Shields. Survey Ophthalmol., 2002, 47, 174-182.
20. Vasantha, R.; Sehgal, P. K.; Panduranga, R. K., Collagen ophthalmic inserts for pilocarpine drug delivery system. Int. J. Pharm. 1988, 47, 95-102.
21. Unterman, S. R.; Rootman, D. S.; Hill, J. M.; Parelman, J. J.; Thompson, H. W.; Kaufman, H. E., Collagen shield drug delivery: therapeutic concentrations of tobramycin in the rabbit cornea and aqueous humor. J. Cataract Refract. Surg. 1988, 14, 500-504.
22. Schwartz, S. D.; Harrison, S. A.; Engstrom, R. E.; Bawden, R. E.; Lee, D. A.; Mondino, B. J. Collagen shield delivery of Amphotericin B. Am. J. Ophthalmol., 1990, 109, 701-704.
23. Lee, B. L.; Matoba, A. Y.; Osato, M. S.; Robinson, N. M., The solubility of antibiotic and corticosteroid combinations. Am. J. Ophthalmol. 1992, 114, 212-215.
24. Hariprasad, S. M.; Shah, G. K.; Chi, J.; Prince, R. Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device. J. Cataract Refractive Surgery, 2005, 31, 2142-2146.
25. Haugen, B.; Werner, L.; Romaniv, N.; Haymore, J.; Kleinmann, G.; Mamalis, N.; Olson, R. J. Prevention of endophthalmitis by collagen shields presoaked in fourth-generation fluoroquinolones versus by topical prophylaxis. J. Cataract Refractive Surgery, 2008, 34, 853-858.
26. Le Bourlais, C.; Acar, L.; Zia, H.; Sado, P. A.; Needham, T.; Leverge, R. Ophthalmic drug delivery systems- recent advances. Prog. Retin. Eye Res., 1998, 17, 33-58.
27. Robinson, J. R.; Mlynek, G. M. Bioadhesive and phase-change polymers for ocular drug delivery. Adv. Drug Delivery Rev., 1995, 16, 45-50.
28. Weinreb, R. N.; Jani, R. A novel formulation of an ophthalmic Badrenoreceptor antagonist. J. Parenteral. Sci. Tech., 1992, 46, 51-53.
29. Tous, S. S.; El Nasser, K. A. Acetazolamide topical formulation and ocular effect. S.T.P. Pharma. Sci. 1992, 2, 125-131.
30. Lehr, C. M.; Yong, H.; Lee, V. H. L. Improved ocular penetration of gentamicin by mucoadhesive polymer polycarbophil in the pigmented rabbit. Invest. Ophthalmol. Vis. Sci., 1994, 35, 2809-2814.
31. Ludwig, A. The use of mucoadhesive polymers in ocular drug delivery. Adv. Drug Del. Rev., 2005, 57, 1595-1639.
32. Burgalassi, S.; Chetoni, P.; Panichi, L.; Boldrini, E.; Saettone, M. F. Xyloglucan as a novel vehicle for timolol: pharmacokinetics and pressure lowering activity in rabbits. J. Ocul. Pharmacol. Ther. 2000, 16, 497-509.
33. Zignani, M.; Tabatabay, C.; Gurny, R. Topical semi-solid drug delivery: kinetics and tolerance of ophthalmic hydrogels. Adv. Drug Deliv. Rev., 1995, 16, 51-60.
34. Tsubota, K.; Dogru, M., Increasing tear quantity with artifical tears and reducing evaporation. In Dry Eye Disease, Asbell, P. A.; Lemp, M. A., Eds. Thieme: New York, 2006; pp 85-94.
35. Winfield, A. J.; Jessiman, D.; Williams, A.; Esakowitz, L. A study of the causes of non-compliance by patients prescribed eyedrops. Br. J. Ophthalmol., 1990, 74, 477-480.
36. Miller, S. C.; Donovan, M. D. Effect of poloxamer 407 gel on the miotic activity of pilocarpine nitrate in rabbits. Int. J. Pharm., 1982, 12, 147-152.
37. Gurny, R., Int J. Preliminary study of prolonged acting drug delivery system for the treatment of glaucoma. Pharm. Acta Helvetica 1981, 56, 130-132.
38. Gurny, R.; Ibrahim, H.; Aebi, A.; Buri, P.; Wilson, C. G.; Washington, N.; Edman, P.; Camber, O., Design and evaluation of controlled release systems for the eye. J. Control Rel., 1987, 6, 367-373.
39. Rozier, A.; Mazuel, C.; Grove, J.; Plazonnet, B. Gelrite: a novel, ion-activated, in situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol. Int. J. Pharm., 1989, 57, 163-168.
40. Van Tomme, S. R.; Storm, G.; Hennink, W. E. In situ gelling hydrogels for pharmaceutical and biomedical applications. Int. J. Pharm., 2008, 355, 1-18.
41. Nesseem, D. I. Ophthalmic delivery of sparfloxacin from in situ gel formulation for treatment of experimentally induced bacterial keratitis. Drug Testing Analysis, 2011, 3, 106-115.
42. Furrer, P.; Plazonnet, B.; Mayer, J. M.; Gurny, R. Application of in vivo confocal microscopy to the objective evaluation of ocular irritation induced by surfactants. Int. J. Pharm., 2000, 207, 89-98.
43. Miyazaki, S.; Suzuki, S.; Kawasaki, N.; Endo, K.; Takahashi, A.; Attwood, D., In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int. J. Pharm. 2001, 229, 29-36.
44. Kumar, S.; Haglund, B. O.; Himmelstein, K. J. In situ-forming gels for ophthalmic drug delivery. J. Ocul. Pharmacol. Ther., 1994, 10, 47-56.
45. Nanjawade, B. K.; Manvi, F. V.; Manjappa, A. S., In situ-forming hydrogels for sustained ophthalmic drug delivery. J. Control Rel., 2007, 122, 119-134.
46. Greaves, J. L.; Wilson, C. G.; Rozier, A.; Grove, J.; Plazonnet, B. Scintigraphic assessment of an ophthalmic gelling vehicle in man and rabbit. Curr. Eye Res., 1990, 9, 415-420.
47. Vandamme, T. F. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog. Retin. Eye Res., 2002, 21, 15-34.
48. Lawrence, M. J.; Rees, G. D. Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev., 2000, 45, 89-121.
49. Naveh, N.; Muchtar, S.; Benita, S. Pilocarpine incorporated into a submicron emulsion vehicle causes an unexpectedly prolonged ocular hypotensive effect in rabbits. J. Ocul. Pharmacol. Therap., 1994, 10, 509-520.
50. Chan, J.; El Maghraby, G. M.; Craig, J. P.; Alany, R. G. Phase transition water-in-oil microemulsions as ocular drug delivery systems: In vitro and in vivo evaluation. 2007, 328, 65-71.
51. Alany, R. G.; Rades, T.; Nicoll, J.; Tucker, I. G.; Davies, N. M. W/O microemulsions for ocular delivery: Evaluation of ocular irritation and precorneal retention. J. Control. Rel., 2006, 111, 145-152.
52. Chan, J.; El Maghraby, G. M.; Craig, J. P.; Alany, R. G., Effect of water-in-oil microemulsions and lamellar liquid crystalline systems on the precorneal tear film of albino New Zealand rabbits. Clin. Ophthalmol., 2008, 2, 1-9.
53. Kayser, O.; Lemke, A.; Hernández-Trejo, N. The impact of nanobiotechnology on the development of new drug delivery systems. Curr. Pharm. Biotechnol., 2005, 6, 3-5.
54. Adibkia, K.; Omidi, Y.; Siahi, M.; Javadzadeh, A.; Barzegar-Jalali, M.; Barar, J.; Maleki, N.; Mohammadi, G.; Nokhodchi, A. Inhibition of endotoxin-induced uveitis by methylprednisolone acetate nanosuspension in rabbits. J. Ocul. Pharmacol. Therap., 2007, 23, 421-432.
55. Ali, Y.; Lehmussaari, K. Industrial perspective in ocular drug delivery. Adv. Drug Deliv. Rev., 2006, 58, 1258-1268.
56. Sahoo, S. K.; Dilnawaz, F.; Krishnakumar, S. Nanotechnology in ocular drug delivery. Drug Discov. Today, 2008, 13, 144-151.
57. Bourges, J. L.; Gautier, S. E.; Delie, F.; Bejjani, R. A.; Jeanny, J. C.; Gurny, R.; BenEzra, D.; Behar-Cohen, F. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest. Ophthalmol. Vis. Sci., 2003, 44, 3562-3569.
58. Zambito, Y.; Di Colo, G. Chitosan and its derivatives as intraocular penetration enhancers. J. Drug Deliv. Sci. Technol., 2010, 20, 45-52.
59. Badawi, A. A.; El-Laithy, H. M.; El Qidra, R. K.; El Mofty, H.; El dally, M. Chitosan based nanocarriers for indomethacin ocular delivery. Arch. Pharm. Res., 2008, 31, 1040-1049.
60. Muller, R. H.; Mader, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery-review of the state of the art. Eur. J. Pharma. Biopharm., 2000, 50 (1), 161-177.
61. Cavalli, R.; Gasco, M.; Chetoni, P.; Burgalassi, S.; Saettone, M. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int. J. Pharm., 2002, 238, 241-245.
62. Cavalli, R.; Morel, S.; Gasco, M. R.; Saettone, M. F.; Chetoni, P. Preparation and evaluation in vitro of colloidal lipospheres containing pilocarpine as ion-pair. Int. J. Pharm., 1995, 117, 243-246.
63. Gonzalez-Mira, E.; Egea, M. A.; Souto, E. B.; Calpena, A. C.; Garcia, M. L. Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery. Nanotechnology, 2011, 22, 1-15.
64. Freitas, C.; Muller, R. H. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur. J. Pharm. Biopharm., 1999, 47, 125-132.
65. Jain, N. K.; Asthana, A. Dendritic systems in drug delivery applications. Expert Opin. Drug Deliv., 2007, 4, 495-512.
66. Tomalia, D. A.; Baker, H.; Dewald, J.; Hall, M.; Martin, S.; Roeck, J.; Ryder, J.; Smith, P. A new class of polymers: Starburst-dendritic macromolecules. Polym. J. 1985, 17, 117-132.
67. Quintana, A.; Raczka, E.; Piehler, L.; Lee, I.; Myc, A.; Majoros, I.; Patri, A. K.; Thomas, T.; Mulé, J.; Baker, J. R. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm. Res., 2002, 19, 1310-1316.
68. Cheng, Y.; Xu, Z.; Ma, M.; Xu, T. Dendrimers as drug carriers: applications in different routes of drug administration. J. Pharm. Sci., 2008, 97, 123-143.
69. Vandamme, T.; Brobeck, L. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J. Control Rel., 2005, 102, 23-38.
70. Greish, K.; Herd, H.; Thiagarajan, G.; Price, R.; Bauer, H.; Yu, T.; Anwar, A.; Ghandehari, H. In Vivo Evaluation of Nanomaterial Biosafety: Evidence of Disseminated Intravascular Coagulopathy (DIC) in Response to Cationic Dendrimer Administration. In 37th Ann. Meeting Exposition Controlled Release Soc., Portland, Oregon, USA, 2010.
71. Boyd, B. J., Characterisation of drug release from cubosomes using the pressure ultrafiltration method. Int. J. Pharm., 2003, 260, 239-47.
72. Spicer, P. T., Progress in liquid crystalline dispersions: Cubosomes. Curr. Opin. Colloid Interface Sci., 2005, 10, 274-279.
73. Gan, L.; Han, S.; Shen, J.; Zhu, J.; Zhu, C.; Zhang, X.; Gan, Y. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone:improving preocular retention and ocular bioavailability. Int. J. Pharm., 2010, 396, 179-187.
74. Zimmer, A. K.; Kreuter, J. Studies on the transport pathway of PBCA nanoparticles in ocular tissues. J. Microencapsul., 1991, 8, 497-504.
75. Kaiserman, I.; Kaiserman, N.; Nakar, S.; Vinker, S. Dry eye in diabetic patients. Am. J. Ophthalmol., 2005, 139, 498-503.
76. Dogru, M.; Katakami, C.; Inoue, M. Tear function and ocular surface changes in noninsulin-dependent diabetes mellitus. Ophthalmology, 2001, 108, 586-592.
77. Akinci, A.; Cetinkaya, E.; Aycan, Z. Dry eye syndrome in diabetic children. Eur. J. Ophthalmol., 2007, 17, 873-878.
78. Gregoriadis, G.; Florence, A. T., Liposomes in drug delivery: clinical, diagnostic and ophthalmic potential. Drugs, 1993, 45, 15-28.
79. Le Bourlias, C. A.; Treupel-Acar, L.; Rhodes, C. T.; Sado, P. A.; Leverge, R. New ophthalmic drug delivery systems. Drug Dev. Ind. Pharm., 1995, 21, 19-59.
80. El-Gazayerly, O. N.; Hikal, A. H. Preparation and evaluation of acetazolamide liposomes as ocular delivery systems. Int. J. Pharm., 1997, 158, 121-127.
81. Uchegbu, I. F.; Vyas, S. P. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int. J. Pharm., 1998, 172, 33-70.
82. Azeem, A.; Anwer, K.; Talegaonkar, S. Niosomes in sustained and targeted drug delivery: some recent advances. J. Drug Targeting, 2009, 17, 671-689.
83. Craig, J. P.; Purslow, C.; Murphy, P. J.; Wolffsohn, J. S. W. Effect of a liposomal spray on the pre-ocular tear film. Contact Lens Anterior Eye 2010, 33, 83-87.
84. Schaeffer, H. E.; Krohn, D. L., Liposomes in topical drug delivery. Invest. Ophthalmol. Vis. Sci., 1982, 22, 220-227.
85. Norley, S. G.; Huang, L.; Rouse, B. T. Targeting of drug loaded immunoliposomes to herpes simplex virus infected corneal cells: an effective means of inhibiting virus replication in vitro. J. Immunol., 1986, 136, 681-685.
86. Bochot, A.; Fattal, E.; Boutet, V.; Deverre, J. R.; Jeanny, J. C.; Chacun, H.; Couvreur, P. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest. Ophthalmol. Vis. Sci. 2002, 43, 253-259.
87. Chetoni, P.; Burgalassi, S.; Monti, D.; Najarro, M.; Boldrini, E., Liposome-encapsulated mitomycin C for the reduction of corneal healing rate and ocular toxicity. J. Drug Deliv. Sci. Technol., 2007, 17 (1), 43-48.
88. Habib, F. S.; Fouad, E. A.; Abdel-Rhaman, M. S.; Fathalla, D. Liposomes as an ocular delivery system of fluconazole: in-vitro studies. Acta Ophthalmol (Copenh) 2010, 88, 901-904.
89. Treblay, C.; Barza, M.; Skoda, F.; Lahav, M.; Baum, J. Reduced toxicity of liposom-associated amphotericin B injected intravitreally in rabbits. Inv. Ophthalmol. Vis. Sci., 1993, 34, 2737-2742.
90. Uchegbu, I. F.; Florence, A. T. Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry. Adv. Colloid Interface Sci., 1995, 58, 1-55.
91. Sahin, N. O. Niosomes as nanocarrier systems. In Nanomaterials and Nanosystems for Biomedical Applications. Mozafari, M. R., Ed. Springer: New York, 2006; pp 67-81.
92. Essa, A. E. Effect of formulation and processing variables on the particle size of sorbitan monopalmitate niosomes. Asian J. Pharma., 2010, 4, 227-233.
93. Saettone, M. F.; Perini, G.; Carafa, M.; Santucci, E.; Alhaique, F. Non-ionic surfactant vesicles as ophthalmic carriers for cyclopentolate. A preliminary evaluation. S.T.P. Pharma. Sci., 1996, 6, 94-98.
94. Vyas, S. P.; Mysore, N.; Jaittley, V.; Venkatesan, N. Discoidal niosome based controlled ocular delivery of Timolol maleate. Pharmazie, 1998, 53, 466-469.
95. Aggarwal, D.; Garg, A.; Kaur, I. P. Development of a topical niosomal preparation of acetazolamide: preparation and evaluation. J. Pharm. Pharmacol., 2004, 56, 1509-1517.
96. Abdelbary, G.; El-gendy, N. Niosomeencapsulated gentamicin for ophthalmic controlled delivery AAPS Pharm. Sci. Tech., 2008, 9, 740-747.
97. Kaur, I. P.; Aggarwal, D.; Singh, H. Improved ocular absorption kinetics of timolol maleate loaded into a bioadhesive niosomal delivery system. Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248, 1467-1472.
98. Fitzgerald, P.; Hadgraft, J.; Kreuter, J.; Wilson, C. G. A gamma-scintigraphic evaluation of microparticulate ophthalmic delivery systems: liposomes and nanoparticles. Int. J. Pharm., 1987, 40, 81-84.
99. Hathout, R. M.; Mansour, S.; Mortada, N. D.; Guinedi, A. S. Liposomes as an ocular delivery system for acetazola mide: In vitro and in vivo studies. AAPS Pharm. Sci. Tech., 2007, 8 (1) (1), E1-E12.
100. Abdelkader, H.; Ismail, S.; Kamal, H.; Alany, R. G. Design and evaluation of controlled release niosomes and discomes for naltrexone hydrochloride ocular delivery. J. Pharm. Sci., 2011, 100, 1833-1846.
101. Uchegbu, I. F.; Schatzlein, A. G.; Vanlerrberghe, G.; Morgatini, N.; Florence, A. T. Polyhedral non-ionic surfactant vesicles. J. Pharm. Pharmacol., 1997, 49, 606-610.
102. Abdelkader, H.; Kamal, H.; Ismail, S.; Alany, R. G. Preparation of niosomes as an ocular delivery system for naltrexone hydrochloride: Physicochemical characterization Pharmazie, 2010, 65, 811-817.
103. Uchegbu, I. F.; Bouwstra, J. A.; Florence, A. T. Large disk-shaped structures (Discomes) in non-ionic surfactant vesicles to micelle transitions. J. Phys. Chem., 1992, 96, 10548-10553.
104. Arunothayanun, P.; Turton, J. A.; Uchegbu, I. F.; Florence, A. T. Preparation and in vitro/in vivo evaluation of luteinizing hormone releasing hormone (LHRH)-loaded polyhedral and spherical/ tubular niosomes. J. Pharm. Sci., 1999, 88, 34-38.
105. Rupenthal, I. D. Ocular delivery of antisense oligonucleotides using colloidal carriers: improving the wound repair after corneal surgery PhD thesis. The University of Auckland, Auckland, 2008.